AGRX
Income statement / Annual
Last year (2023), Agile Therapeutics, Inc.'s total revenue was $19.59 M,
an increase of 80.02% from the previous year.
In 2023, Agile Therapeutics, Inc.'s net income was -$14.47 M.
See Agile Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$19.59 M |
$10.88 M |
$4.10 M |
$749.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$8.98 M
|
$6.84 M
|
$10.72 M
|
$282.00 K
|
$163.00 K
|
$23.00 K
|
$23.00 K
|
$19.00 K
|
$18.00 K
|
$0.00
|
| Gross Profit |
$10.62 M
|
$4.05 M
|
-$6.62 M
|
$467.00 K
|
-$163.00 K
|
-$23.00 K
|
-$23.00 K
|
-$19.00 K
|
-$18.00 K
|
$0.00
|
| Gross Profit Ratio |
0.54
|
0.37
|
-1.61
|
0.62
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.23 M
|
$3.25 M
|
$6.25 M
|
$13.50 M
|
$9.86 M
|
$9.78 M
|
$14.43 M
|
$20.93 M
|
$25.62 M
|
$13.37 M
|
| General & Administrative Expenses |
$10.51 M
|
$11.86 M
|
$14.70 M
|
$12.74 M
|
$9.00 M
|
$8.74 M
|
$12.38 M
|
$8.79 M
|
$7.47 M
|
$5.15 M
|
| Selling & Marketing Expenses |
$17.77 M
|
$30.37 M
|
$43.44 M
|
$23.29 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.27 M
|
$42.23 M
|
$58.14 M
|
$36.02 M
|
$9.00 M
|
$8.74 M
|
$12.38 M
|
$8.79 M
|
$7.47 M
|
$5.15 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$30.50 M
|
$45.48 M
|
$64.39 M
|
$49.52 M
|
$18.86 M
|
$18.52 M
|
$26.81 M
|
$29.72 M
|
$33.09 M
|
$18.52 M
|
| Cost And Expenses |
$39.48 M
|
$52.32 M
|
$75.11 M
|
$49.80 M
|
$18.86 M
|
$18.52 M
|
$26.81 M
|
$29.72 M
|
$33.09 M
|
$18.52 M
|
| Interest Income |
$78.00 K
|
$80.00 K
|
$25.00 K
|
$309.00 K
|
$252.00 K
|
$366.00 K
|
$282.00 K
|
$117.00 K
|
$5.00 K
|
$2.56 K
|
| Interest Expense |
$1.42 M
|
$3.13 M
|
$3.91 M
|
$3.11 M
|
$0.00
|
$1.12 M
|
$1.92 M
|
$2.33 M
|
$2.07 M
|
$1.56 M
|
| Depreciation & Amortization |
$386.00 K
|
$1.53 M
|
$2.22 M
|
$276.00 K
|
$163.00 K
|
$23.00 K
|
$23.00 K
|
$19.00 K
|
$18.00 K
|
$12.55 K
|
| EBITDA |
-$12.66 M |
-$25.42 M |
-$64.93 M |
-$48.47 M |
-$18.61 M |
-$19.54 M |
-$26.51 M |
-$29.72 M |
-$33.09 M |
-$18.50 M |
| EBITDA Ratio |
-0.65
|
-2.34
|
-15.83
|
-64.71
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.01
|
-3.81
|
-17.31
|
-65.49
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.42 M
|
$11.35 M
|
-$62.00 K
|
-$2.80 M
|
$252.00 K
|
-$1.74 M
|
-$1.49 M
|
-$2.10 M
|
-$3.22 M
|
-$1.22 M
|
| Income Before Tax |
-$14.47 M
|
-$30.09 M
|
-$74.89 M
|
-$51.85 M
|
-$18.61 M
|
-$20.26 M
|
-$28.30 M
|
-$31.82 M
|
-$36.31 M
|
-$19.73 M
|
| Income Before Tax Ratio |
-0.74
|
-2.76
|
-18.26
|
-69.23
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$4.68 M
|
$1.69 M
|
$0.00
|
-$163.00 K
|
-$477.00 K
|
$0.00
|
-$3.08 M
|
-$5.97 M
|
-$3.65 M
|
| Net Income |
-$14.47 M
|
-$25.41 M
|
-$76.59 M
|
-$54.69 M
|
-$18.44 M
|
-$19.78 M
|
-$28.30 M
|
-$28.74 M
|
-$30.34 M
|
-$16.08 M
|
| Net Income Ratio |
-0.74
|
-2.33
|
-18.67
|
-73.01
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-6.71 |
-58.79 |
-63115.49 |
-1291.56 |
-746.2 |
-1152.82 |
-1829.61 |
-2033.18 |
-2755.72 |
-2822.01 |
| EPS Diluted |
-6.71 |
-58.79 |
-63115.49 |
-1291.56 |
-746.2 |
-1152.82 |
-1829.61 |
-2033.18 |
-2755.72 |
-2822.01 |
| Weighted Average Shares Out |
$2.16 M
|
$432.22 K
|
$1.21 K
|
$42.34 K
|
$24.72 K
|
$17.16 K
|
$15.47 K
|
$14.14 K
|
$11.01 K
|
$5.70 K
|
| Weighted Average Shares Out Diluted |
$2.16 M
|
$432.22 K
|
$1.21 K
|
$42.34 K
|
$24.72 K
|
$17.16 K
|
$15.47 K
|
$14.14 K
|
$11.01 K
|
$5.70 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
